Glucagon analogues
The invention provides materials and methods for promoting weight loss or preventing weight gain, and in the treatment of diabetes, metabolic syndrome and associated disorders. In particular, the invention provides novel glucagon analogue peptides effective in such methods. The peptides may mediate their effect by having increased selectivity for the GLP-1 receptor as compared to human glucagon.
1. A compound having the formula R 1 —X—Z—R 2
wherein
R 1 is H, C 1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl;
R 2 is OH or NH 2 ;
X is a peptide which has the formula I:
(SEQ ID NO: 4)
His-Ser-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-
Tyr-Leu-Asp-Glu-Arg-Arg-Ala-Lys-Asp-Phe-Ile-Glu-
Trp-Leu-Leu-Ser-Ala
or differs from formula I at up to 4 of the following positions whereby, if different from formula I:
the residue at position 16 is selected from: Ser, Asp, Lys;
the residue at position 18 is: Ala;
the residue at position 20 is selected from: Gln, Arg, Glu;
the residue at position 23 is: Val;
the residue at position 24 is selected from: Gln, Asp, Lys, Arg;
the residue at position 27 is selected from: Met;
the residue at position 28 is selected from: Asn, Arg, Lys, Ala; and
the residue at position 29 is Thr;
and Z is absent or a sequence of 1-20 amino acid units selected from the group consisting of Ala, Leu, Ser, Thr, Tyr, Cys, Glu, Lys, Arg, Dbu, Dpr and Orn;
or a pharmaceutically acceptable salt thereof.
2. A compound according to claim 1 wherein X differs from formula I at up to 4 of the following positions whereby, if different from formula I:
the residue at position 16 is selected from: Ser, Asp, Lys;
the residue at position 20 is selected from: Gln, Arg, Glu;
the residue at position 27 is selected from: Met; and
the residue at position 28 is selected from: Asn, Arg, Ala.
3. A compound according to claim 2 wherein X differs from formula I at up to 3 of the following positions whereby, if different from formula I:
the residue at position 16 is selected from: Ser, Asp, Lys; and
the residue at position 20 is selected from: Gln, Arg, Glu.
4. A compound according to claim 1 wherein X differs from formula I at up to 3 of the following positions whereby, if different from formula I:
the residue at position 16 is selected from: Ser, Asp, Lys;
the residue at position 18 is: Ala; and
the residue at position 20 is selected from: Gln, Arg, Glu.
5. A compound according to claim 1 wherein peptide X differs from formula I at up to 4 of the following positions whereby, if different from formula I:
the residue at position 23 is: Val;
the residue at position 24 is selected from: Gln, Asp, Lys, Arg;
the residue at position 27 is selected from: Met; and
the residue at position 28 is selected from: Asn, Arg, Ala.
6. A compound according to any of the preceding claims wherein the residues at positions 16 and 20, and/or 20 and 24 are capable of forming a salt bridge.
7. A compound according to any one of the preceding claims wherein X comprises one or more of the following sets of residues:
(a) 20-Lys, 24-Glu;
(b) 20-Lys, 23-Ile, 24-Glu;
(c) 16-Glu, 20-Lys, 24-Glu;
(d) 16-Glu, 20-Lys;
(e) 16-Glu, 20-Lys, 29-Ala;
(f) 16-Glu, 20-Lys, 23-Ile, 24-Glu;
(g) 16-Glu, 20-Lys, 23-Ile, 24-Glu, 29-Ala;
(h) 16-Glu, 20-Lys, 24-Glu, 29-Ala;
(i) 20-Lys, 23-Ile, 24-Glu, 29-Ala;
(j) 27-Leu, 28-Ser, 29-Ala;
(k) 29-Ala;
(l) 16-Ser;
(m) 20-Gln;
(n) 23-Val;
(o) 24-Gln;
(p) 16-Ser, 20-Gln;
(q) 16-Asp, 20-Arg, 24-Asp;
(r) 16-Lys, 20-Glu;
(s) 24-Arg; or
(t) 28-Arg.
8. A compound according to claim 1 wherein X has the sequence:
HSQGTFTSDYSKYLDSRRAKDFIEWLLSA;
(SEQ ID NO: 13)
HSQGTFTSDYSKYLDERRAQDFIEWLLSA;
(SEQ ID NO: 5)
HSQGTFTSDYSKYLDERRAKDFVEWLLSA;
(SEQ ID NO: 6)
HSQGTFTSDYSKYLDERRAKDFIQWLLSA;
(SEQ ID NO: 7)
HSQGTFTSDYSKYLDSRRAQDFIEWLLSA;
(SEQ ID NO: 8)
HSQGTFTSDYSKYLDDRRARDFIDWLLSA;
(SEQ ID NO: 9)
HSQGTFTSDYSKYLDKRRAEDFIKWLLSA;
(SEQ ID NO: 10)
HSQGTFTSDYSKYLDERRAKDFIRWLLSA;
(SEQ ID NO: 11)
HSQGTFTSDYSKYLDERRAKDFIEWLLRA;
(SEQ ID NO: 12)
HSQGTFTSDYSKYLDERAAKDFIEWLLSA;
(SEQ ID NO: 14)
HSQGTFTSDYSKYLDERRAKDFIDWLLSA;
(SEQ ID NO: 15)
HSQGTFTSDYSKYLDERRAKDFIEWLLAA;
(SEQ ID NO: 16)
or
HSQGTFTSDYSKYLDERRAKDFIEWLLSA.
(SEQ ID NO: 17)
9. A compound according to any one of the preceding claims wherein R 1 is H.
10. A compound according to any one of the preceding claims wherein R 2 is NH 2 .
11. A compound according to any one of the preceding claims wherein Z has no more than 25% sequence identity with the corresponding portion of the IP-1 sequence of human oxyntomodulin having the sequence Lys-Arg-Asn-Arg-Asn-Asn-Ile-Ala.
12. A compound according to any one of the preceding claims wherein Z has a Cys as the C-terminal residue.
13. A compound according to claim 1 wherein Z is absent.
14. A compound according to claim 1 wherein one or more of the amino acid side chains in the compound is conjugated to a lipophilic substituent or a polymeric moiety.
15. A nucleic acid encoding a compound according to claim 1 .
16. An expression vector comprising a nucleic acid according to claim 15 .
17. A host cell comprising a nucleic acid according to claim 15 or an expression vector according to claim 16 .
18. A pharmaceutical composition comprising a compound according to claim 1 , in admixture with pharmaceutically acceptable carrier.
19. A method of reducing weight gain, promoting weight loss, or for treatment of a condition, said condition morbid obesity, obesity linked inflammation, obesity linked gallbladder disease, and obesity induced sleep apnea, or for treatment of insulin resistance, glucose intolerance, type 2 diabetes, said method comprising administering a therapeutically effective amount of a compound according to claim 1 .
20. A compound according to claim 14 , wherein one or more of the amino acid side chains in peptide X is conjugated to said lipophilic substituent or polymeric moiety.
21. A pharmaceutical composition comprising a nucleic acid according to claim 15 , in admixture with a pharmaceutically acceptable carrier.
22. A pharmaceutical composition comprising an expression vector according to claim 16 , in admixture with a pharmaceutically acceptable carrier.
23. A pharmaceutical composition comprising a host cell according to claim 17 , in admixture with a pharmaceutically acceptable carrier.
24. The compound of claim 1 , wherein X has the sequence: HSQGTFTSDYSKYLDSRRAKDFIEWLLSA (SEQ ID NO:13).
25. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAQDFIEWLLSA (SEQ ID NO:5).
26. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFVEWLLSA (SEQ ID NO:6).
27. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIQWLLSA (SEQ ID NO:7).
28. The compound of claim 1 , wherein X has the sequence: HSQGTFTSDYSKYLDSRRAQDFIEWLLSA (SEQ ID NO:8).
29. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDDRRARDFIDWLLSA (SEQ ID NO:9).
30. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDKRRAEDFIKWLLSA (SEQ ID NO:10).
31. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIRWLLSA (SEQ ID NO:11).
32. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIEWLLRA (SEQ ID NO:12).
33. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERAAKDFIEWLLSA (SEQ ID NO:14).
34. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIDWLLSA (SEQ ID NO:15).
35. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIEWLLAA or (SEQ ID NO:16).
36. The compound of claim 1 , wherein X has the sequence:
HSQGTFTSDYSKYLDERRAKDFIEWLLSA (SEQ ID NO:17).